The National Food and Drug Surveillance Institute (INVIMA) in Colombia has approved Johnson & Johnson’s (J&J) single-shot Covid-19 vaccine for emergency use.

Reuters reported that the vaccine is developed by J&J’s pharmaceutical wing Janssen.

The Colombian Government had entered an agreement with J&J to obtain nine million doses of this vaccine.

The news agency quoted INVIMA director Julio Cesar Aldana as saying in a government’s nightly broadcast: “In its capacity as regulator, INVIMA has authorised the emergency use of the vaccine from the pharmaceutical company Janssen of the multinational J&J.

“In addition to being a one-dose vaccine, the J&J vaccine has less demanding storage needs than some other approved vaccines.”

At present, Colombia has approved the use of vaccines developed by Pfizer and BioNTech, AstraZeneca and Sinovac.

The country has closed deals for vaccines by Pfizer and BioNTech, AstraZeneca, Moderna and Sinovac while it is set to get vaccine doses through the COVAX mechanism backed by the World Health Organization (WHO).

More than 2.35 million Covid-19 cases and more than 62,500 deaths were reported in the country, which has administered over 1.38 million vaccine shots and anticipates inoculating around 70% of its people to achieve herd immunity.

Meanwhile, the Thailand Food and Drug Administration (FDA) granted emergency use authorisation to Janssen’s single-dose Covid-19 vaccine.

Thailand Deputy Prime Minister and Public Health Minister Anutin Charnvirankul told reporters that the Thai FDA approved the vaccine, which is the third to get authorised in the country after those of AstraZeneca and Sinovac.

According to the Center for the Covid-19 Situation Administration (CCSA) report, Thailand reported 97 Covid-19 cases on 25 March with total confirmed cases standing at 28,443.

Last week, WHO issued Emergency Use Listing (EUL) for the vaccine for individuals aged 18 years and above.

On another note, the Russian Direct Investment Fund (RDIF) and ChemRar Group announced the registration of Russian anti-Covid Favipiravir-based drug Avifavir by the National Agency of Drug and Food Control (BPOM) in Indonesia.